Skip to main content

Advertisement

Table 1 Distribution of patients by baseline clinical variables.

From: Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO

Variable Category Number (%)
   N = 664
Sex Female 311 (46.8)
  Male 353 (53.2)
Age Less than 75 years 496 (74.7)
  75 years or older 168 (25.3)
Chemotherapy CHOP 334 (50.3)
  PMitCEBO 330 (49.7)
GCSF No 330 (49.7)
  Yes 334 (50.3)
Stage I 70 (10.5)
  II 176 (26.5)
  III 193 (29.1)
  IV 225 (33.9)
B symptoms No 311 (46.8)
  Yes 353 (53.2)
ECOG Performance status 0 206 (31.0)
  1 264 (39.8)
  2 131 (19.7)
  3 39 (5.9)
  4 13 (2.0)
  No data 11 (1.7)
Plasma LDH concentration (mU/L)   
  Normal (0.2–0.5) 216 (32.5)
  Elevated (> 0.5) 381 (57.4)
  No data 67 (10.1)
Bone marrow aspirate Not involved 508 (76.5)
  Involved 57 (8.6)
  No data 99 (14.9)
Bone marrow trephine Not involved 487 (73.3)
  Involved 89 (13.4)
  No data 88 (13.3)